Industry momentum is trending in favor of single-use bioreactors as a plurality of biopharma companies are opting for the disposable version of bioreactors, according to new market research. Let's look at the drivers of this change, regional analysis, and prominent vendors in the space.
- Why Royalty Financing Is A Smart Funding Alternative For Small Life Science Companies
- FDA Introduces Quality Management Maturity Program
- How To Lose A Batch In 10 Days
- The Regulatory Genome: “Digital Software” For Drug Development
- Understanding The FDA’s Current Focus On Risk Evaluation And Mitigation Strategies
- Pragmatic Computational Biology With Andrew Satz
- Allogeneic Cell Therapy: Our Strategy, Learnings, & Advice
- Essential Elements Of Technology Transfer
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Large Volume Tris And DPBS Buffer Preparation
Explore a solution for efficiently mixing sinking powders that tend to accumulate on the bottom and in the corners of the bag.
-
Understanding & Enhancing Natural History Studies’ Value In Rare Diseases
Registry and natural history studies can be very important to the clinical development of therapeutics in rare diseases. To accommodate these advances in knowledge, study design flexibility is a must.
-
Implementing High Cell Density Cryopreservation In Your Seed Train
Simplify seed train intensification with high cell density cryopreservation. Eliminate the need for manual scale-up steps and enable risk reduction through closed banking and inoculation processes.
-
A Simple Flow Cytometry-Based Assay For Detecting CAR Expression
Learn more about fluorescent-labeled recombinant proteins that allow chimeric antigen receptors (CARs) to be directly stained and detected by flow cytometry.
-
Scale From Cell Factory Systems To A Bioreactor Without Affecting CQAs
The challenge was to identify an effective, replicable, and large-scale LVV manufacturing process to meet the growing manufacturing demand without affecting critical quality attributes.
-
CHO Culture: Bioprocess Modes Batch Fed-Batch and Perfusion
Explore the differences between three cell culture bioprocesses using bench-scale CHO cells, and why tracking specific parameters is important to achieving the inoculation of bioreactors at high viability.
-
How Dwell Volume And Extra-Column Volume Impact Method Transfer
Understand how system factors like dwell volume and extra-column volume contribute to method performance across labs and how this knowledge can increase the success of method transfer.
-
Genome Editing of Human Primary T Cells With Lipid Nanoparticles
We show CRISPR/Cas9-mediated knockouts of the T cell receptor and explore multi-step LNP engineering to produce TCRɑβ KO CAR T cells, a promising approach towards allogeneic CAR T cell therapy.
-
Improve Productivity In CHO-K1, CHO-S, And DG44 Cells
This commercially available platform can enhance process productivity and reduce development time, thereby enabling potential reductions in manufacturing costs and accelerating time-to-market.
-
Evaluating A Flexible LC Platform
Learn about a premier system offering a flexible LC platform that can be broadly deployed across labs to support the analytical needs in the development and manufacturing of biotherapeutics.
NEWSLETTER ARCHIVE
- 09.29.23 -- Flexibility For Advanced Manufacturing Facilities
- 09.29.23 -- Innovative Solutions To Ensure CGT Commercial Success
- 09.28.23 -- Advancing CAR T Cell Strategies
- 09.28.23 -- Dr. Peter Marks On The Future Of Genome Editing
- 09.27.23 -- Enabling Faster Development Timelines With Novel Characterization Approaches

CELL AND GENE CONTENT COLLECTIONS

While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections